Figure 5From: Targeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoterThe TRAIL gene expression in brain tumor cells: (A) Cells were treated with Ad/CMV-GFP at 1000 MOI VPs/ cell at 3 days. (B) Cells were treated with Ad/gTRAIL at 1000 MOI VPs/ cell at 3 days. Protein levels were analyzed by Western blot analysis after the treatment. β-actin was used as loading control.Back to article page